Authors' reply
We read with interest the comments of lung and Priem which arose from our earlier publication I and we note they are not concerned with the data in that paper but rather in a general approach to the assay of N-acetyl-I1-D-glucosaminidase (NAG) in urine. They outline three conditions which should be met before a particular assay is acceptable for use in analytical laboratories. The first criterion concerns the necessity to avoid tedious pre-treatment to eliminate interfering substances found in urine, and the second states that the assay should be readily adaptable to equipment in common use in clinical chemistry laboratories. We have no quarrel with either of Letters 503 these points, but would add the rider that there are many types of laboratories often with a small throughput of samples and in this case manual and semi-automated procedures might suffice. We take issue with the third point, which implies that unless a procedure is in the form of a kinetic (continuous) assay, it is not of value for the routine assay of urinary NAG activity. Most clinical chemistry laboratories use a wide range of different types of automated equipment many of which are designed for discontinuous assays.
Indeed an assay we developed is based on 2-methoxy-4-(2' -nitrovinyl)-phenyl-N-acetyl-l1-D-glucosaminide (MNP-GlcNAc) is available commercially as a substrate or a kit (PPR Diagnostics Ltd, London, UK) and has been adapted for all the major autoanalysers. We commented previously on the 3,3 I -dichlorophenolsulphonphthaleinyl-N-acetyll1-glucosaminide (CPR) assay-and we still have serious reservations regarding its use. lung et
01.
3 report the pH optima of NAG isoenzymes as broad maxima between pH 4· 2 and 4·8 and they state that 'this can also be assumed for other substrates', which agrees with our finding" but they then contradict this by reporting that the optimum pH for CPR-GlcNAc is 5' 25 but do not record activities below pH 5·0. We note that the pH recommended by lung and Priem in their letter is 6' 25 well away from either of the reported optima for this enzyme.
lung and Priem in their letter compare 4-nitrophenol-N-acetyl-l1-glucosaminide (PNP-GlcNAc) with ammonium 5-[4-(2-acetamido-2-deoxY-I1-Dglucopyranosyloxy)-3-methoxyphenylmethylene] -2-thioxothiazolidin-4-one-3-ethanoate (VRAGlcNAc) and since they had comparable activities towards NAG suggested that there are no advantages to be gained by using VRA-GlcNAc. However, since VRA-GlcNAc produces a phenol with 2'18 times greater absorption than that from PNP-GlcNAc, then there is a clear advantage. Further, they imply that VRA-GlcNAc is more expensive than PNP-GlcNAc and this is not the case as their prices are comparable. The added sensitivity means, e.g., that the incubation time can be reduced and the additional sensitivity can be of value for the analysis of dilute samples. lung and Priem correctly point out that the sensitivity of an assay at the low levels of activity is most important as the assay of NAG is often used as an early indicator of renal dysfunction/ damage.
In an earlier paper lung and Priem' compare the use of CPR-GlcNAc and PNP-GlcNAc for the Letters differentiation of healthy and cadmium exposed workers. PNP-GIcNAc easily differentiates these groups whereas the CPR-GIcNAc method leads to some overlap. The relative activities of CPRGlcNAc and PNP-GlcNAc are given as 1:3' 82 by Meier et al:" and as I :2· 38. 5 If it is assumed that the ratio is approximately I : 3 then CPR-GlcNAC has only 15070 of the sensitivity of VRA-GIcNAC (ratio I: 6·5), a fact which users should bear in mind.
A further problem is encountered with the kinetic assay namely the effect of urea. lung and Priem suggest (see their Fig. 2 ) that at approximately 830 mM urea, there is approximately 87070 of activity remaining, in contrast Klein 7 notes that only 80070 is left at 833 mM urea. We reported" that the inhibition is increased at higher pH values at which uncompetitive inhibition occurs to a greater extent.
In summary, VRA-GIcNAc is a sensitive, readily water soluble substrate which operates at the pH optimum of the enzyme and at saturation. It therefore meets all the customary requirements for a precision enzyme assay without the need for the pretreatment of the urine.
R G PRICE Biochemistry Section, Division of Life Sciences, King's College, Campden Hill Road, London W8 7AH, UK
